A Model for Risk-Based Screening and Prioritization of Human Exposure to Chemicals from Near-Field Sources.

Exposure- and risk-based assessments for chemicals used indoors or applied to humans (i.e., in near-field environments) necessitate an aggregate exposure pathway framework that aligns chemical exposure information from use sources to internal dose and eventually to their potential for health effects. Such a source-to-effect continuum is advocated to balance the complexity of human exposure and the insufficiency of relevant data for thousands of existing and emerging chemicals. Here, we introduce the Risk Assessment, IDentification And Ranking-Indoor and Consumer Exposure (RAIDAR-ICE) model, which establishes an integrated framework to evaluate human exposure due to indoor use and direct application of chemicals to humans. As a model evaluation, RAIDAR-ICE faithfully reproduces exposure estimates inferred from biomonitoring data for 37 chemicals with direct and indirect near-field sources. RAIDAR-ICE generates different rankings for 131 chemicals based on different exposure- and risk-based assessment metrics, demonstrating its versatility for diverse chemical screening goals. When coupled with a far-field RAIDAR model, the near-field RAIDAR-ICE model enables assessment of aggregate human exposure. Overall, RAIDAR-ICE is a powerful tool for high-throughput screening and prioritization of human exposure to neutral organic chemicals used indoors.

Safer Sterile Compounding: Choosing and Using Disinfectants for the Cleanroom.

Compounders worldwide are responsible for ensuring that the sterile preparations they dispense are pure, potent, and safe. To achieve that result, proper cleaning and disinfection of International Organization for Standardization controlled environments must occur. Because those tasks must be performed according to established standards, the compounding pharmacist must research regulatory requirements and appropriate products for use. In this report, we focus on U.S. regulations, guiding entities, and effective products that enable compliance with the increasingly stringent procedures required for pharmaceutical compounding. We also review cleaning and disinfecting processes, discuss the importance of correctly choosing and using disinfectants and/ or sporicidal disinfectants with surface claims in the cleanroom, and provide answers to questions frequently asked by staff who use those agents. In addition, we profile specific disinfectants that are compliant with United States Pharmacopeia Chapter <797> and current good manufacturing practice standards. Biological safety cabinets and compounding aseptic containment isolators must undergo an additional process that deactivates hazardous drug residues and removes them from the interior surfaces of those devices before they are cleaned and disinfected, but that discussion is beyond the scope of this article.

SAFER STERILE COMPOUNDING: Choosing and Using Disinfectants for the Cleanroom.

Compounders worldwide are responsible for ensuring that the sterile preparations they dispense are pure, potent, and safe. To achieve that result, proper cleaning and disinfection of International Organization for Standardization controlled environments must occur. Because those tasks must be performed according to established standards, the compounding pharmacist must research regulatory requirements and appropriate products for use. In this report, we focus on U.S. regulations, guiding entities, and effective products that enable compliance with the increasingly stringent procedures required for pharmaceutical compounding. We also review cleaning and disinfecting processes, discuss the importance of correctly choosing and using disinfectants and/ or sporicidal disinfectants with surface claims in the cleanroom, and provide answers to questions frequently asked by staff who use those agents. In addition, we profile specific disinfectants that are compliant with UnitedStates Pharmacopeia Chapter <797> and current good manufacturing practice standards. Biological safety cabinets and compounding aseptic containment isolators must undergo an additional process that deactivates hazardous drug residues and removes them from the interior surfaces of those devices before they are cleaned and disinfected, but that discussion is beyond the scope of this article.